Guidance for the procurement of COVID‐19 convalescent plasma: differences between high‐ and low‐middle‐income countries

Abstract

There has been wide-scale adoption of CCP in many HICs, which could increase if clinical trials show efficacy of use. By contrast, LMICs, having received little attention, require locally applicable strategies for adoption of CCP.